Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Cancer Research and Clinic ; (6): 87-90, 2014.
Artigo em Chinês | WPRIM | ID: wpr-447232

RESUMO

Objective To compare the efficacy,toxicity and prognosis on treating advanced non-small-cell lung cancer (NSCLC) between using weekly docetaxel (DOC) and using DOC associated with nedaplatin(NDP).Methods 56 cases of NSCLC patients were retrospectively analyzed.Group A included 34 cases who were treated with weekly DOC (35 mg/m2,dl,8).Group B included 22 cases who were treated with DOC associated with NDP (DOC 35 mg/m2,dl,8,NDP 80 mg/m2,d2).One treatment cycle was 21 days.Efficacy,toxicity and prognosis were evaluated after 2 treatment cycles.Results RR of group A was 8.8 % (3/34).RR of group B was 27.3 % (6/22).DCR of group A was 50.0 % (17/34).DCR of group B was 63.6 % (14/22).PFS of group A was 2.3 months.PFS of group B was 5.1 months.OS of group A was 8.7 months.OS of group B was 10.5 months.1-year survival rate of group A was 26.5 %.1-year survival rate of group B was 31.8 %.The above comparisons were not statistically different (all P > 0.05).In adverse reactions,hematologic toxicity in group B was greater than that in group A (x2 =4.877,P =0.027).Other adverse reactions such as gastrointestinal reactions,fatigue and so on were grade Ⅰ-Ⅱ.Conclusions The treatment of weekly DOC used in advanced NSCLC is safe,effective an low toxicity.There are no significant difference of RR and PFS between single DOC and DOC associated with NDP.

2.
Cancer Research and Clinic ; (6)2000.
Artigo em Chinês | WPRIM | ID: wpr-543362

RESUMO

Objective To observe the effects of improving tumor cell hypoxia on radiotherapy in non-small cell lung cancer(NSCLC). Methods Forty-two patients with NSCLC on stage II to stage IV were enrolled randomly, of whom 38 patients were well documented. All patients were treated with oxygenator by intravenous oxygen delivery within thirty minutes before radiotherapy to increase partial pressure of blood oxygen and improve tumor cell hypoxia. The arterial blood gas was analysed for each patients before and after oxygen infusion. All patients receive radiotherapy at a dosage of 2 Gy each time per day, five times per week. The total dosage was 60 to 70 Gy. Another 37 NSCLC patients selected randomly in control group were treated by conventional radiotherapy. The therapeutic effects were analysed statistically according to WHO categorized standard. Results The mean PO2 was (85.6?7.5) mm Hg, (103?9.7) mm Hg, and SaO2 was (89.5?6.1) %, (94.4?5.2) % before and after oxygen infusion respectively in study group. The efficacy of radiotherapy was 63.16 %(24/38), which was higher than that in control group 43.24 % (16/37) (0.05

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA